Establishment Labs (NASDAQ:ESTA) Trading Down 5.5% - Here's Why

Key Points

• Establishment Labs Holdings Inc. shares decreased by 5.5% during mid-day trading, with the stock last trading at $36.22 after reaching a low of $35.93.
• Wall Street analysts have mixed ratings on the stock, with an average rating of "Moderate Buy" and a target price of $55.80, while Needham & Company maintains a "buy" rating with a target price of $48.00.
• The company reported a quarterly revenue of $51.30 million, exceeding expectations, but posted a loss of ($0.57) earnings per share, missing consensus estimates.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) dropped 5.5% on Thursday . The stock traded as low as $35.93 and last traded at $36.22. Approximately 48,508 shares traded hands during trading, a decline of 91% from the average daily volume of 535,006 shares. The stock had previously closed at $38.34.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ESTA. Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a report on Saturday. Mizuho raised their target price on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Needham & Company LLC reiterated a "buy" rating and set a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. BTIG Research started coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target for the company. Finally, Citigroup boosted their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research note on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $55.80.

Establishment Labs Stock Down 1.4%

The firm has a 50-day simple moving average of $40.75 and a two-hundred day simple moving average of $37.15. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. The stock has a market cap of $1.09 billion, a P/E ratio of -12.36 and a beta of 0.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The firm had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.80 million. During the same period last year, the company posted ($0.62) EPS. The business's revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. Equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Establishment Labs during the first quarter valued at approximately $207,000. New York State Common Retirement Fund purchased a new stake in Establishment Labs during the first quarter valued at about $894,000. Northern Trust Corp boosted its position in Establishment Labs by 53.9% during the 4th quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after buying an additional 9,865 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Establishment Labs by 15.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock valued at $2,196,000 after acquiring an additional 6,307 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in shares of Establishment Labs by 650.0% in the 4th quarter. Vestal Point Capital LP now owns 300,000 shares of the company's stock valued at $13,821,000 after purchasing an additional 260,000 shares during the period. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.